Cost-Effectiveness of HIV Testing and Treatment in the United States
Open Access
- 15 December 2007
- journal article
- review article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 45 (Supplement), S248-S254
- https://doi.org/10.1086/522546
Abstract
In September 2006, the US Centers for Disease Control and Prevention (CDC) released new guidelines calling for routine, voluntary human immunodeficienKeywords
This publication has 36 references indexed in Scilit:
- The Lifetime Cost of Current Human Immunodeficiency Virus Care in the United StatesMedical Care, 2006
- The Survival Benefits of AIDS Treatment in the United StatesThe Journal of Infectious Diseases, 2006
- Optimal Allocation of Testing Dollars: The Example of HIV Counseling, Testing, and ReferralMedical Decision Making, 2005
- Cost-Effectiveness of Screening for HIV in the Era of Highly Active Antiretroviral TherapyNew England Journal of Medicine, 2005
- Expanded Screening for HIV in the United States — An Analysis of Cost-EffectivenessNew England Journal of Medicine, 2005
- The Case for Earlier Treatment of HIV InfectionClinical Infectious Diseases, 2004
- The Cost Effectiveness of Combination Antiretroviral Therapy for HIV DiseaseNew England Journal of Medicine, 2001
- Preevaluation of Clinical Trial Data: The Case of Preemptive Cytomegalovirus Therapy in Patients with Human Immunodeficiency VirusClinical Infectious Diseases, 2001
- The Cost-Effectiveness of Fluconazole Prophylaxis against Primary Systemic Fungal Infections in AIDS PatientsMedical Decision Making, 1997
- Guidelines for authors and peer reviewers of economic submissions to the BMJBMJ, 1996